General
Preferred name
fluvastatin
Synonyms
FLUVASTATIN SODIUM ()
Fluvastatin (D6 sodium) ()
XU 62320 D6 sodium ()
XU 62320 ()
XU 62320 sodium ()
XU-62-320 ()
Fluvastatin sodium salt ()
XU 62-320 (D6) ()
(3R,5S)-Fluvastatin (sodium) ()
Fluvastatin (sodium) ()
fluvastatin93957-54-1 ()
(3R,5S)-XU 62-320 ()
XU 62-320 (free acid) ()
XU 62-320 ()
Fluvastatin (XU-62-320) Sodium ()
Vastin,XU-62-320 ()
Fluvastatin-d6 (sodium salt) ()
P&D ID
PD002988
CAS
93957-55-2
94061-80-0
93957-54-1
Tags
natural product
drug
available
Drug indication
Hypercholesterolaemia
Drug Status
approved
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Fluvastatin is a member of the cholesterol-lowering statin family of drugs. The approved drug is a racemic mixture of a 3R, 5S isomer and a 3S, 5R isomer, and this is supported by the INN document which also indicates a racemate. The 3R, 5S isomer (shown here, and in the PubChem link below) is more pharmacologically active . The other isomer is represented by CID 1548972. Representations of the stereochemistry of fluvastatin shown on the resources linked to below may vary from the structure shown here. The majority of the references we cite for our biological activity data do not specify whether the racemate or a specific stereoisomer were used in their experiments.
(GtoPdb)
DESCRIPTION
Fluvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR) with IC50 of 8 nM. It belongs to a class of the statin drug and is structurally distinct from the fungal derivatives of this therapeutic class. It binds of the substrate HMG-CoA with Ki value of 0.3 nM but not with respect to binding of NADPH. It is marketed under the trade name Lescol® and is used to treat hypercholesterolemia and to prevent cardiovascular disease. It induces G2/M phase arrest and has antilipemic effect.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
20
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugMAP
DrugMAP Approved Drugs
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
NIH Clinical Collections (NCC)
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
39
Molecular Weight
411.18
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
3
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
3
cLogP
4.63
TPSA
82.69
Fraction CSP3
0.29
Chiral centers
2.0
Largest ring
6.0
QED
0.5
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Autophagy
HMG-CoA Reductase (HMGCR)
HMG-CoA Reductase
HMGCR
Ferroptosis
Pathway
Metabolic Enzyme/Protease
Metabolism
Apoptosis
MOA
HMG-CoA Reductase inhibitor
HMGCR inhibitor
Indication
hypercholesterolemia, congenital heart defects
Disease Area
endocrinology, cardiology
Therapeutic Class
Anticholesteremic Agents
Solubility
10 mM in DMSO
Source data
